SCHEMBL2952145

SCHEMBL2952145

CC(C)(C)OC(=O)N1CCC(CSc2ccccc2)(Nc2ccc(S(N)(=O)=O)cc2[N+](=O)[O-])CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 9/20 0.52
BCL2 P10415 6/20 0.52
MAPT P10636 8/20 0.46
GAA P10253 5/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
GPR119 Q8TDV5 1/20 0.42
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KMT2A Q03164 2/20 0.40
PKM P14618 1/20 0.40
MAPK1 P28482 1/20 0.40
DOT1L Q8TEK3 1/20 0.39
MMP2 P08253 1/20 0.38
MMP13 P45452 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2944141 0.87 MAPT (0.51) BCL2L1BCL2MAPTGAAALDH1A1
SCHEMBL2944642 0.82 BCL2L1 (0.52) BCL2L1BCL2MAPTGAAALDH1A1
SCHEMBL1959604 0.82 MAPT (0.51) BCL2L1BCL2MAPTGAAALDH1A1
SCHEMBL2950293 0.82 BCL2L1 (0.68) BCL2L1BCL2
SCHEMBL26648466 0.78 BCL2L1 (0.60) BCL2L1BCL2
SCHEMBL26648462 0.78 BCL2L1 (0.60) BCL2L1BCL2
SCHEMBL22581464 0.77 MAPT (0.50) BCL2L1BCL2MAPTGAAALDH1A1
SCHEMBL30414834 0.77 MAPT (0.50) BCL2L1BCL2MAPTGAAALDH1A1
SCHEMBL1700248 0.76 MAPT (0.53) BCL2L1BCL2MAPTGAAALDH1A1
SCHEMBL31344646 0.74 MAPT (0.52) BCL2L1BCL2MAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 BCL2L1 4/4885BCL2 3/4885MAPT 4830/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR BCL2L1 6/4885BCL2 2/4885MAPT 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.